Topical sucralfate in the management of peristomal skin disease: an open study.
Dermatoses affecting the skin around stoma sites are common and difficult to treat. We have investigated the effectiveness of topical sucralfate in the management of peristomal dermatoses in adults using an open study design. Apart from forming a physical barrier to further irritation, sucralfate binds to basic fibroblast growth factor preventing its degradation and thereby promotes healing. In eight out of nine patients with faecal or urine erosions, daily, topical sucralfate treatment was associated with healing within 4 weeks. There was limited or no response to treatment in a further nine patients with traumatic ulcers, excoriated dermatitis or pyoderma gangrenosum. Topical sucralfate represents a safe, inexpensive and effective therapeutic intervention, particularly for those patients with high output or short stomas where repeated stoma leakage may be unavoidable.
Lyon
C C
CC
Dermatology Centre, University of Manchester, and the Pharmacy and the Department of Stoma-Care, Hope Hospital, Salford, UK. clyon@fs1.ho.man.ac.uk
Stapleton
M
M
Smith
A J
AJ
Griffiths
C E
CE
Beck
M H
MH
D000005:Abdomen; D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012871:Skin Diseases / Q000188:drug therapy*; D013392:Sucralfate / Q000008:administration & dosage*; D054047:Surgical Stomas / Q000009:adverse effects*; D016896:Treatment Outcome
D000897:Anti-Ulcer Agents; D013392:Sucralfate